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Ovarian cancer has a poor prognosis, with different
outcomes for different patients. The mechanism un-
derlying this poor prognosis and heterogeneity is
not well understood. We have developed an unbi-
ased, adaptive clustering approach to integratively
analyze ovarian cancer genome-wide gene expres-
sion, DNA methylation, microRNA expression, and
copy number alterationprofiles.Weuncovered seven
previously uncategorized subtypes of ovarian cancer
that differ significantly in median survival time. We
then developed an algorithm to uncover molecular
signatures that distinguish cancer subtypes. Surpris-
ingly, although thegood-prognosis subtypes seem to
have not been functionally selected, the poor-prog-
nosis ones clearly have been. One subtype has an
epithelial–mesenchymal transition signature and a
cancer hallmark network, whereas the other two sub-
types are enriched for a network centered on SRC
and KRAS. Our results suggest molecular signatures
that are highly predictive of clinical outcomes and
spotlight ‘‘driver’’ genes that could be targeted by
subtype-specific treatments.INTRODUCTION
Ovarian cancer is the second most common and the most lethal
gynecologic cancer, representing about 3% of all cancers diag-
nosed in females, with a median incidence at 63 years of age
(Jemal et al., 2008; Kosary, 2007). Unlike many other cancers,
the prognosis of ovarian cancer is poor and has not been signif-
icantly improved over recent decades, with a 5-year survival rate
of around 47% (Johannes, 2010).542 Cell Reports 4, 542–553, August 15, 2013 ª2013 The AuthorsThe underlying mechanisms for the poor prognosis of ovarian
cancer are largely unknown. Despite treatment with similar sur-
gery and adjuvant therapies, outcomes may be very different
among different patients. A recent genome-wide association
study (GWAS) identified a common variant at 19p13 associated
with the survival time of ovarian cancer (Bolton et al., 2010).
However, to date, many other GWAS studies have not been
convincingly replicated.
The Cancer Genome Atlas (TCGA) has collected detailed
clinical records and heterogeneous high-throughput data for
more than 500 cases of ovarian serous cystadenocarcinoma,
including gene expression, somatic mutation, promoter DNA
methylation, microRNA (miRNA) expression, and copy number
alteration (CNA) (Cancer Genome Atlas Research Network,
2011). From these data, the TCGA consortium found ten recur-
rent somatic mutations, including TP53, BRCA1/2, and RB1, in
high-grade ovarian cancers and identified four transcriptional
subtypes that were unrelated to prognosis (Cancer Genome
Atlas Research Network, 2011). They showed that the
mutual exclusivity of the BRCA1/2 mutation and CCNE1 ampli-
fication is related to ovarian cancer prognosis (Ciriello et al.,
2012). Up to now, however, the question of whether ovarian
cancer subtypes with different prognoses and distinct hallmark
hazard factors exist has remained unclear. The TCGA data
set gives us a unique opportunity to investigate whether
combining all of these heterogeneous high-throughput data
will allow us to (1) uncover hallmark hazard factors to distin-
guish subtypes with different prognoses, and (2) identify sub-
type-specific pathways that might explain such different
prognoses.
Here, we developed an adaptive clustering algorithm based on
the Bayesian Information Criterion (BIC) to automatically deter-
mine the optimal number of sample and feature clusters, and
coupled this with deep clustering using our recently developed
unsupervised ‘‘super k-means’’ algorithm on a combination
of gene expression, DNA methylation, miRNA expression, and
CNA data for ovarian cancer. With this approach, we were able
Table 1. Numbers of Samples and Features of the Types of
High-Throughput Data Used in this Study
Data Type Platform
Number of
Samples
Number of
Features
mRNA
expression
Agilent 244K Custom Gene
Expression G4502A-07-1
513 17,436
DNA
methylation
Illumina HumanMethylation27 513 12,854
miRNA
expression
Agilent 8 3 15K Human
miRNA-Specific Microarray
510 799
CNA of
genes/miRNA
Agilent 1M 512 20,412/628to de novo detect seven distinct subtypes with significantly
different clinical outcomes. In addition, we developed an algo-
rithm to systematically uncover molecular signatures that best
distinguish the seven subtypes of ovarian cancer from the clus-
tering result. The in-depth analysis of these molecular signatures
not only broadens our current understanding of ovarian cancer
but also sheds light on ways to achieve better diagnosis and
treatment of this disease in the future.
RESULTS
Selection of Ovarian Cancer Hazard Factors
We first investigated whether we could identify hazard factors
for ovarian serous cystadenocarcinoma. From the TCGA, we
collected and preprocessed the clinical records and four types
of high-throughput data of 513 patients together with their sur-
vival time from initial diagnoses to death, or to the last follow-
up if they were still alive at the time of the TCGA study (Table 1;
Experimental Procedures; Cancer Genome Atlas Research
Network, 2011). All four types of data (messenger RNA [mRNA]
and miRNA expression, promoter DNA methylation, and CNA)
were available for 509 of the 513 samples. One sample lacked
copy number data, and three other samples lacked miRNA
expression data (Table 1). We used the 512 samples that had
both gene expression and copy number data for analysis.
The Cox proportional hazard model (Cox regression model) is
widely used with censored data to estimate the effect of different
features on survival time (Andersen and Gill, 1982). To investi-
gate which features are related to the prognosis of ovarian can-
cer, we first used the univariate Cox proportional hazard model
to perform a regression analysis between each feature and the
patients’ survival time. In total, we selected 4,526 features as
hazard factors (p < 0.05; Experimental Procedures), including
1,651 mRNA expression changes, 455 promoter DNA methyl-
ation changes, 140 miRNA expression changes, and CNAs of
2,191 genes and 89 miRNAs.
De Novo Characterization of Ovarian Cancer Subtypes
by Molecular Signatures
To unbiasedly identify ovarian cancer subtypes with different
types of features represented with equal probability, we per-
formed adaptive clustering on the 512 samples to uncover sub-
types of samples that showed different survival times using all of
the above-described 4,526 features (hazard factors) simulta-neously (Experimental Procedures). To reduce systematic varia-
tions among heterogeneous high-throughput data from different
platforms, we normalized the 4,526 features against normal tis-
sue controls (Experimental Procedures). Because there is no a
priori knowledge about the number of ovarian cancer subtypes,
we first applied the BIC (Schwarz, 1978) to these normalized
data, which automatically determined the optimal number of
clusters across the 512 samples to be seven, and across the
4,526 features to be 37 (Experimental Procedures; Figures S1A
and S1B). Because BIC is mainly aimed at determining the right
number of clusters and does not generate the most compact
clustering result, we subsequently used the unsupervised super
k-means clustering algorithm (Liu et al., 2013), which generates
extremely compact clusters, to cleanly divide the samples into
seven clusters, which we refer to hereafter as ‘‘subtypes,’’ and
similarly to divide the features into 37 clusters (Experimental
Procedures; Figure 1A).
Since the data for the 512 samples were generated in 13
batches (Cancer Genome Atlas Research Network, 2011), we
examined whether our subtype clustering result could have
been due to batch effects. Fisher’s exact tests showed that
none of the seven subtypes were significantly enriched in
any of the 13 batches (Experimental Procedures). They also
confirmed that neither the selection of hazard factors nor the
clustering approach was biased toward particular batches.
In order to examine the stability of the subtype clustering
result, we performed 10-fold cross validation by randomly
dividing the 512 samples into ten groups and hiding 10% of
the samples each time to perform the super k-means clustering
algorithm. The subtype classification was observed to be very
stable, with the average sensitivity and precision both exceeding
87% (Figure 1D, empirical p value < 1e-04; Experimental Proce-
dures). Remarkably, the accuracy stayed at the same level
when in each round the remaining independent 10% of samples
were assigned to the nearest cluster centers of the 90% (Fig-
ure 1E). This demonstrates the existence of robust molecular
signatures that distinguish the de novo categorized ovarian
cancer subtypes.
We then designed an algorithm to systematically uncover the
molecular signatures for each of the seven ovarian cancer
subtypes from the clustering results (Extended Experimental
Procedures) and in this way identified 18 of the most significant
subtype-association signature feature clusters (Extended
Results). We found that using just two features from each of
the selected 18 clusters (36 features in total) was sufficient to
achieve high subtype-identification accuracy (81%), indicating
that the 36 signature features are a good candidate marker set
for ovarian cancer classification (Extended Results; Figures
S1C and S1D; Tables S1 and S2).
Our algorithm identified distinct features for six of the seven
subtypes. These include a deletion of chr6 (p24.1-p12.1) in
subtype 1, upregulation of three gene expression clusters in
subtype 2, amplification of multiple chromosomes in subtypes
4–6, and deletion of chr19 (q13.2-q13.43) in subtypes 6 and 7
(Figures 1A and 1B).
Remarkably, patients with the seven subtypes of ovarian can-
cer differ significantly in their survival time. The median survival
times of the subtypes with the shortest and longest prognosesCell Reports 4, 542–553, August 15, 2013 ª2013 The Authors 543
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Table 2. Enriched GO Terms of the Subtype-2-Specific Upregulated Genes
Term p Value Fold Enriched Symbols
GO:0007155 j cell adhesion 3.55E-08 3.67 SPON2, COL16A1, SPOCK1, COL6A6, SVEP1, SLAMF7, THBS2,
THBS1, CTGF, WISP1, CYR61, ADAM12, ITGA5, CD93, LAMB1,
COL3A1, ECM2, CDH11, PDPN, CLDN11, AEBP1, CCL11, ITGB1,
KAL1, COL8A2, COL8A1, ANTXR1, SIRPA, FN1, CD36, COL5A1
GO:0019838 j growth factor binding 4.19E-07 9.19 THBS1, CTGF, WISP1, TGFBR1, CYR61, IL18R1, COL3A1, HTRA1,
KDR, TGFBR2, CD36, COL5A1
GO:0040011 j locomotion 9.56E-07 4.33 PLAUR, WWP1, ARID5B, CTGF, TGFBR1, CYR61, FAP, ETS1, ITGA5,
CXCL14, SBDS, C5AR1, SCG2, TWIST1, AGTR1, CCL11, ITGB1, KAL1,
FN1, COL5A1, RNASE2
GO:0001525 j angiogenesis 7.33E-06 7.84 THBS1, FGF1, CTGF, ANXA2, KDR, SCG2, BMP4, COL8A2, COL8A1,
FN1, ELK3
GO:0050431 j TGF-b binding 1.24E-04 32.48 THBS1, TGFBR1, TGFBR2, CD36
GO:0008284 j positive regulation of
cell proliferation
1.89E-03 3.01 FGF1, TGFBR1, PRRX1, LAMB1, IGF1, BNC1, FABP4, KDR, GAS1,
SCG2, TGFBR2, BMP4, KRT6A, CCL11, ADRA2A
GO:0005520 j IGF binding 2.14E-03 13.53 CTGF, WISP1, CYR61, HTRA1are 2.36 and 4.72 years, respectively, representing a difference
of 2.0-fold (log-rank test, p = 3.16e-04; Figures 1B and 1C).
The 164 patients (32.0%) in subtypes 2, 4, and 5 have a poor
prognosis, with a median survival time of <3 years, whereas
the 213 patients (41.6%) in subtypes 3 and 7 have a better
(good) prognosis, with a median survival time of >4.5 years (Fig-
ures 1B and 1C). Therefore, in this way, the majority of patients
(73.6%) can be successfully assigned into either high- or low-
risk groups using our adaptive clustering approach.
In addition to the above subtypes, patients in subtypes 1 and 6
have a median survival time in between those of the high- and
low-risk groups (Figures 1B and 1C). Interestingly, subtype 6
has both the signature of a multiple chromosome amplification
similar to that of subtypes 4 and 5, which have a poor prognosis,
and the signature of a chr19 (q13.2-q13.43) deletion similar to
that of subtype 7, which has a good prognosis. Because subtype
6 shows a moderate survival time compared with the high- and
low-risk groups (Figures 1A–1C), these signatures may oppose
each other in survival. However, it remains formally possible
that the two signatures of this subtype might reflect a combina-
tion of tumor cells from two different origins with different alter-
ations in their genomes.
Finally, it is worth noting that these poor-prognosis subtypes
could not be correctly identified by transcriptomic data alone,
even when prognosis-related genes were used for clustering
(Figures S1E and S1F).Figure 1. De Novo Categorization of Ovarian Cancer Subtypes
(A) Super k-means clustering of the 512 TCGA ovarian cancer samples (columns)
The normalized value of each feature is indicated by color intensity, with yellow/
compared with the controls. The subtype-specific signature clusters are labeled
(B) Systematically categorized ovarian cancer subtype classification feature cluste
time of each subtype, and the major data type for each feature cluster are also l
(C) Overall survival probabilities (y axis) are plotted against the survival times (year
data are indicated by a ‘‘+’’ at their censoring time (last follow-up). The survival cur
comparison. Overall survival is defined as in the Cancer Genome Atlas Research N
date of death or last follow-up.
(D and E) The average sensitivity and precision for each subtype on the training (
samples of (A) (used as benchmarks here) in ten trails of clustering with 10% of
See also Figure S1 and Tables S1 and S2.Functional Analysis of Signature Feature Clusters
When we examined the Gene Ontology (GO) terms (Ashburner
et al., 2000) and Kyoto Encyclopedia of Genes and Genomes
(KEGG) (Kanehisa et al., 2010) pathways enriched among the
subtype signatures, we found that genes that are specifically
upregulated in subtype 2 are enriched for many functions
related to tumorigenesis, such as cell adhesion, angiogenesis,
transforming growth factor b (TGF-b) binding, and positive
regulation of cell proliferation (Table 2). Among them, the
most significantly enriched was the ‘‘cell adhesion’’ function
(Table 2), which is related to metastasis. This may well explain
the poor prognosis of subtype 2 (Figures 1B and 1C). Clinical
records revealed that the 70 patients in subtype 2 showed
higher pathological tumor stages (stage IIIC or IV) compared
with other patients (Wilcoxon rank sum test, p = 8.995e-3).
The higher pathological stages, stages III and IV, indicate
metastasis, with IV showing more extensive metastasis than
III. Interestingly, when we compared the 70 patients in sub-
type 2 with the 81 patients of tumor stage IV (the highest
stage), we found that their median survival times were similar,
whereas the 5-year survival rate of subtype 2 was even worse
than that of tumor stage IV (Figure 2). This indicates that the
subtype 2 features we found at the molecular level are at
least a comparable, or possibly even better, indication of
poor prognosis than the clinical observation of distant
metastasis.using the 4,526 features that are significantly associated with prognosis (rows).
blue representing higher/lower expression, copy number, and promoter DNA
at the left side of the heatmap.
rs. These clusters are derived from (A). The number of patients, median survival
isted.
s, x axis) of the seven ovarian cancer subtypes. Samples with censored survival
ve of all 512 patients as well as the 0.95 confidence intervals are also shown for
etwork (2011), i.e., as the interval from the date of initial surgical resection to the
D) or testing set samples (E) are compared with the original subtypes in all 512
the samples left out in each trial. Error bars indicate the SDs of ten trails.
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Figure 2. Comparison of Survival Curves between Subtype 2 and
Stage IV Ovarian Cancer Patients
Overall survival probabilities (y axis) are plotted against the survival times
(years, x axis) of subtype 2 or stage IV ovarian cancer patients. Samples with
censored survival data are indicated by a ‘‘+’’ at their censoring time (last
follow-up). The survival curve of all 512 patients with 0.95 confidence intervals
is also shown for comparison.The epithelial–mesenchymal transition (EMT) and an embry-
onic stem cell (ESC)-like gene expression signature have been
associated with malignancy and metastasis in human tumors
(Ben-Porath et al., 2008; Polyak and Weinberg, 2009). Through
a literature cocitation analysis, we found that the frequency of
literature cocitation of the term ‘‘epithelial mesenchymal transi-
tion’’ or ‘‘embryonic stem cells’’ with the genes specifically
upregulated in subtype 2 was significantly higher than random
expectation (empirical p value < 0.001 for both terms; Experi-
mental Procedures). In fact, the genes that are specifically upre-
gulated in subtype 2 are enriched in the key regulators and
signaling pathways of the EMT, such as SNAI1, TWIST1, and
the TGF-b pathway, as summarized by Polyak and Weinberg
(2009) (Figure 3). Moreover, the genes that are specifically upre-
gulated in subtype 2 are also enriched in NOS (NANOG, OCT4,
and SOX2) targets that were previously identified in a chromatin
immunoprecipitation (ChIP)-chip experiment in human ESCs
(hESCs) (Boyer et al., 2005; Figure 3), even though the expres-
sion of OCT4, NANOG, SOX2, MYC, and KLF4 themselves is
not increased in subtype 2. This indicates that the tumor cells
in this subtype contain at least a partial hESC-like gene expres-
sion signature. Taken together, these findings support the
hypothesis that an EMT and hESC-like gene expression signa-
turemay have key roles in cancermetastasis and poor prognosis
(Polyak and Weinberg, 2009).
Intriguingly, we did not find more somatic mutations among
the subtype 2 samples on the subtype 2 signature genes.
This prompted us to investigate whether any nonmutational or
epigenetic mechanisms are involved in maintaining the upregu-546 Cell Reports 4, 542–553, August 15, 2013 ª2013 The Authorslation of subtype 2 signature genes. Given the requirements for
histone demethylase KDM5A and the insulin growth factor 1
(IGF-1) signaling pathway for drug resistance in cancer stem
cells (CSCs) (Sharma et al., 2010), we also examined the
expression, CNA, and promoter DNA methylation status of
these genes across the subtypes. The copy number and
expression of KDM5A, which are highly correlated across the
512 samples (Pearson correlation coefficient [PCC] = 0.73),
are relatively low in good-prognosis subtypes (subtypes 3
and 7) and high in other subtypes. IGF1 is specifically upregu-
lated in subtype 2 (the metastasis subtype) and downregulated
in other subtypes (Wilcoxon rank sum test, p = 2.997e-16).
Similarly, IGFBP3 is also upregulated in subtype 2 compared
with the other subtypes (Wilcoxon rank sum test, p =
3.717e-7). However, the classical CSC markers CD133 and
CD44 are generally repressed in all subtypes compared with
normal tissue controls (Wilcoxon rank sum test, p = 4.212e-3
for CD133 and p = 6.619e-6 for CD44; Figure 3). Therefore,
although they lack classical CSC markers, in general, the
ovarian cancer samples with a poor prognosis possess a
recently discovered drug-resistant CSC feature: high expres-
sion of KDM5A and IGF1. Indeed, the poor-prognosis subtypes
(subtypes 2, 4, and 5) have the worst outcomes in response to
drug treatment and are more likely to be resistant to cancer
drug treatments than other subtypes (Figure S2; Tables S3,
S4, and S5).
A Functional Interaction Network for the Signature
Genes
Wenext investigated the relationship among the signature genes
of each subtype using a functional interaction network. To enrich
for the ‘‘driver’’ genes (i.e., those genes in which changes are
directly reflected at the gene expression level), we first removed
the genes that were identified by genomic or epigenomic signa-
tures (CNA or DNA methylations) that are not consistent with
gene expression changes (PCC < 0.3 for CNAs, PCC > 0.3
for promoter DNA methylations; Figure S3; Extended Experi-
mental Procedures). We then also removed the genes with
inconsistent direction of expression changes within the featured
subtype (with dominant direction in <60% samples; Figure 1B).
To distinguish the driver events from the ‘‘passengers,’’ we
further focused on the signature genes that were within
cancer-hallmark-related pathways (annotated according to
Hanahan and Weinberg, 2000, 2011), ESC pluripotency signal-
ing pathways (http://www.cellsignal.com/reference/pathway/
ESC_pluripotency.html), multi-drug-resistance factors (http://
www.biocarta.com/pathfiles/h_mrppathway.asp), or EMT signal-
ing pathways (Polyak and Weinberg, 2009; Experimental Proce-
dures). Finally, we mapped the signature genes present in the
hallmark pathways to an accurately curated human functional
protein interaction network to study their functional relationships
(Wu et al., 2010; Experimental Procedures).
The resulting network was observed to be highly modular, with
the genes in similar pathways clustered together (Figure 4B). In
particular, the signature genes that were upregulated in subtype
2 or amplified in subtypes 4–6 were largely enclosed by four
network modules (Figure 4; see the yellow nodes/signature for
cluster 2 and the blue nodes/signature for clusters 4–6).
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Figure 3. EMT and hESC-Related Genes,
Drug-Resistance Signatures, and CSC
Markers in Ovarian Cancer Subtypes
(A) Enriched EMT- and hESC-related genes spe-
cifically upregulated in subtype 2.
(B) Heatmap of EMT- and hESC-related genes,
drug-resistance signatures, and CSC markers in
ovarian cancer subtypes. The normalized value of
each feature compared with the normal tissue
controls is indicated by color intensity, with yellow/
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values except for the row marked ‘‘KDM5A
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See also Figure S2 and Tables S3, S4, and S5.Interestingly, the signature genes for the subtypes with relatively
good prognosis did not show up in the hallmark network or clus-
ter into tightly connected modules, indicating that poor prog-
nosis, but not good prognosis, is associated with functional se-
lections at the network level.
In this network, we found that the genes that were specifically
upregulated in subtype 2 predominantly participated in three
modules corresponding to the functions ‘‘focal adhesion
and extracellular matrix (ECM)-receptor interaction,’’ ‘‘TGF-b
signaling pathway,’’ and ‘‘Wnt signaling pathway,’’ which are all
related toEMTandmetastasis (Figure4).Remarkably, thenetwork
module of ‘‘proliferation circuits (mTOR, ErbB, and mitogen-acti-
vated protein kinase [MAPK] signaling pathways)’’ is enriched for
genes specifically amplified in subtypes 4–6, including several
key regulators in these pathways, such as KRAS, SRC, PLCG1,
andAKT2 (Figure 4). Another key transcription factor,E2F1, which
regulates the cell cycle, was also specifically amplified in these
three subtypes. The network model suggests that in these sub-
types, multiple signaling pathways related to cell proliferation
and the cell cycle might be constitutively activated through
genomic amplification of these key regulators, which in turnwould
accelerate the division and proliferation of tumor cells, thus
contributing to the poor prognosis of subtypes 4 and 5.Cell Reports 4, 542–553Validation of Subtype 2
Classification by Independent
Sample Sets
To determine whether our subtype-spe-
cific molecular signatures derived from
the TCGA data are also applicable to a
completely independent set of samples,
we collected the expression profiles of
696 high-grade serous ovarian carcinoma
samples used in a recent prognostic
study (Verhaak et al., 2013) from five inde-
pendent data sets (Bonome et al., 2008;
Crijns et al., 2009; Denkert et al., 2009;
Tothill et al., 2008; Yoshihara et al.,
2010). Then, we used k-means clustering
to group samples from each of the five in-
dependent data sets into two clusters
based on the expression profiles of sub-type 2 signature genes (note that only 170–214 out of the 222
signature genes are quantified in the five data sets). We found
that most of our predicted subtype 2 samples were indeed clas-
sified as a ‘‘mesenchymal’’ (MES) subtype in the previous prog-
nostic study (Verhaak et al., 2013), and only a few of them fall into
the ‘‘immunoreactive’’ (IMR) subtype (Figure 5A). Almost no sam-
ples in subtype 2 fall into the other two subtypes classified by
Verhaak et al. (2013). Moreover, patients in the predicted sub-
type 2 cluster also have a significantly shorter survival time
(log-rank test, p = 1.11e-05) than the other patients, which inde-
pendently confirmed that subtype 2 has a poor prognosis. Spe-
cifically, the median survival times for patients in the predicted
subtype 2 group and the other group are 30 versus 47.4 months,
respectively, representing a 1.58-fold difference (Figure 5B),
which is even larger than the difference we found in the TCGA
data set (1.36-fold, 33.36 versus 45.36 months, respectively;
Figures 1B and 1C). Furthermore, we also examined the relation-
ship among all available survival-related factors with the two-
group partition of patients from the five independent data sets.
Patients in the predicted subtype 2 cluster are associated with
a high rate of platinum resistance and have more advanced tu-
mor stages (Wilcoxon rank sum test, p = 1.993e-6 and 1.422e-
3, respectively), and are also more likely to relapse (log-rank, August 15, 2013 ª2013 The Authors 547
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Ovarian Cancer Subtypes
(A) Heatmap of subtype-specific features in the
seven subtypes of ovarian cancer samples. The
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interactions are indicated by the edge style, with
solid lines representing manually curated path-
ways, and dashed lines representing predicted
interactions. The network modules were manually
dissected based on the network structure and
gene functions, with their most concordant func-
tions labeled above them.
See also Figure S3.test, p = 4.2e-03; Figure 5E), whereas factors such as tumor
grade, tumor residue disease, and patients’ age at initial diag-
nosis do not differ greatly between the groups (Figures 5C and
5D). The association between subtype 2 and more advanced tu-
mor stages is consistent with our observations from the TCGA
data set, and once again suggests a possible link between sub-
type 2 signatures and metastasis.
Since subtype 2 is associated with advanced tumor stages
(Figure 5C), we tested whether this is the main cause for the
poor prognosis of patients in this subtype by comparing the
prognoses of subtype 2 and non-subtype 2 patients from
the five independent data sets after stratifying for tumor stage.
Remarkably, within tumor stage III, which comprises the vast
majority of patients (85.5%), subtype 2 patients still show
significantly shorter survival times than the rest of the patients
at stage III (log-rank test, p = 2.92e-04, Figure 5F). The other
two stages (stages II and IV), however, do not show significant
differences in prognosis between subtype 2 and other patients
(Figure 5F), which might simply be due to the small number of
patients in the two stages and/or the influence of other factors,548 Cell Reports 4, 542–553, August 15, 2013 ª2013 The Authorssuch as surgical and drug interventions.
Similarly, in the TCGA data set, we also
observed differences in prognosis for
subtype 2 versus other patients after
stratifying for tumor stage factor. Within
either tumor stage IIIC or IV of the
TCGA samples, subtype 2 patients
showed a significantly shorter survival
time than the rest of the patients at thesame stage (Figure S4A; log-rank test, p = 4.92e-03 and
2.36e-02, respectively).
However, samples of one stage are frequently classified into
many different subtypes and have very different survival times,
indicating that the clinical diagnosis of stage has a much lower
resolution than our subtyping (Figure S4B).
To conclude, the significant difference in prognosis between
subtype 2 patients and other patients in stage III indicates that
our subtype 2’s associationwith short survival timecannot be sim-
ply attributed to the factor of tumor stages. Given the fact that sub-
type-2-specific upregulated genes are enriched for metastasis-
related functions (e.g., cell adhesion and EMT), these genes
provide additional resolution for identifying the molecular features
of thismetastaticdisease (Figures5FandS4), and thusprovideex-
tra information for more effective targeted treatment in the future.
DISCUSSION
In this study, we have established an analysis framework to sys-
tematically, automatically, and unbiasedly uncover signature
features and pinpoint the potential driver genes of each subtype.
We first combined high-throughput genomic, epigenomic, and
transcriptomic data and used theCox proportional hazardmodel
to select features associated with patient survival time in ovarian
cancer. We then developed an adaptive clustering algorithm to
automatically determine the optimal number of sample and
feature clusters based on the BIC. Following this, we deep clus-
tered samples/features using our recently developed super
k-means algorithm. This approach led to the de novo categoriza-
tion of seven distinct ovarian cancer subtypes with significantly
different clinical outcomes.
The signatures identified include a metastasis, EMT, and par-
tial hESC-like gene expression signature (Ben-Porath et al.,
2008; Polyak and Weinberg, 2009) for subtype 2, and a recently
reported drug-resistance signature (Sharma et al., 2010) for
poor-prognosis subtypes (subtypes 2, 4, and 5). In contrast to
Ciriello et al.’s hypothesis about themutual exclusivity in network
modules (Ciriello et al., 2012), we found that the signature genes
of a subtype tend to be concentrated in the same modules in our
network, indicating their potential synergistic effects. In partic-
ular, the genes that are upregulated in the three poor-prognosis
subtypes via transcriptomic and genomic alterations are highly
interconnected in the network through pathways related to
metastasis, EMT, and cell proliferation. Our automated analysis
framework could easily be applied to similar studies of other
types of cancer.
In the original TCGA study, using 1,500 differentially ex-
pressed genes, researchers identified four ovarian cancer sub-
types; however, these subtypes did not differ significantly in
survival time (Cancer Genome Atlas Research Network, 2011).
Nevertheless, the TCGA investigators did select a 193-gene
expression signature associated with survival, and a recent anal-
ysis revealed a 100-gene signature associated with prognosis
(Verhaak et al., 2013). Although the latter signature does overlap
significantly with our combined seven subtype signatures, the
biggest difference is that previous studies used supervised ap-
proaches to build a prognosis predictor to maximize the differ-
ence in survival time between poor and good groups, whereas
our approach uses unsupervised learning to identify intrinsicmo-
lecular subtypes of ovarian cancers de novo. Using our
approach, we observed a difference in prognosis between
different subtypes based on their distinct molecular signatures,
but we did not set out to maximize this difference at the begin-
ning of the analysis. Therefore, our approach offers a more
unbiased molecular signature and mechanism to develop
personalized treatment compared with the approach of Verhaak
et al. (2013), which masked the intrinsic distinction of molecular
programs among subtypes with similar prognosis status. As a
result, the patients in Verhaak et al.’s studywho had similar prog-
noses were deprived of the chance of being differentially treated
by targeting their distinct molecular hallmarks.
A more recent study also used a clustering approach to iden-
tify five ovarian cancer subtypes based on the gene expression
profiles of 1,538 tumor samples, and further used a small hairpin
RNA (shRNA) library to screen for molecular targets that are
essential for cell growth in a subtype of poor prognosis (Tan
et al., 2013). Similarly to the study by Verhaak et al. (2013), that
study was based solely on expression profiles, whereas ourapproach combines genomic, epigenomic, and transcriptomic
data, and identified five (out of seven) subtypes with clear CNA
signatures. Interestingly, Tan et al. (2013) also identified a
poor-prognosis subtype characterized by ‘‘mesenchymal’’
genes that overlap significantly with our subtype 2 signature
genes (Fisher’s exact test, p < 2.2e-16). This again implies the
universal existence of this signature in most sample collections.
However, the poor-prognosis subtypes 4 and 5, which show
amplification of the proliferation-related genes centered on
KRAS and SRC, were identified only by our approach.
From a methodological perspective, Tan et al. (2013) used
consensus clustering (CC) (Monti et al., 2005) to detect five
tumor subtypes (clusters) based on gene expression data. It is
worth noting that CC is only able to identify a small number of
clusters (usually fewer than ten) within data due to its limited
discriminative power. As a result, it can be used to decide the
number of tumor subtypes, but not the number of molecular
signature clusters (which is often much larger). In contrast, our
adaptive clustering approach can be used for either task,
enabling a comprehensive characterization of the subtype-
feature relationships (as shown by the biclustering result in
Figure 1A).
The clinical observation-based classification of ovarian cancer
includes cancer staging (IA–IV), which assesses the extent of
cancer spreading, and cancer grading (G1–G3), whichmeasures
the differentiation of cancer cells. For the TCGA data, both the
cancer-grade- and cancer-stage-based subtype classifications
are not exclusively correlated with our seven subtypes, except
for subtype 2, which is significantly associatedwith advanced tu-
mor stages (IIIC and IV; Wilcoxon rank sum test, p = 8.995e-3).
Compared with the molecular-signature-based classifications,
these clinical classifications have much lower resolution for pre-
dicting prognosis, for two main reasons: (1) Most of the patients
are assigned to a single advanced grade (86.2% patients are as-
signed to G3) or to a single advanced stage (71.2% patients are
assigned to IIIC), with a difference between the shortest- and
longest-prognosis cancer grades or tumor stages of 1.3- or
1.7-fold (log-rank test, p = 3.77e-02 or 8.71e-04when comparing
tumor grade G3 versus G1+G2 or tumor stage IV versus IA–IIIB).
However, with our adaptive clustering approach, 32.0% and
41.6% patients are assigned to high- and low-risk groups,
respectively, with a more significant difference of 2.0-fold be-
tween the shortest- and longest-prognosis subtypes (log-rank
test, p = 3.16e-04; Figures 1B and 1C). (2) Samples of one stage
are frequently classified into many different subtypes and have
very different survival times. In the case of stage IIIC samples,
they can be classified into all seven subtypes and show signifi-
cant differences in survival (Figure S4B). Therefore, the molecu-
lar-signature-based subtype classification has its own merit
beyond classifications based on clinical observations.
Our network also provides hints for designing specific
treatment protocols for different ovarian cancer subtypes. For
example, the metastasis and EMT of subtype 2 cases conceiv-
ably could be attenuated by known anticancer drugs that target
the upregulated ECM receptor ITGB1 (volociximab) or the
vascular endothelial growth factor (VEGF) receptor KDR (suniti-
nib and sorafenib). Additionally, drugs that are not currently
used in clinical treatments may also be worth trialing for subtypeCell Reports 4, 542–553, August 15, 2013 ª2013 The Authors 549
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Figure 5. Validation of the Subtype 2 Classification Using an Independent Sample Set
(A) Number of overlapping patients between the predicted subtype 2 and the subtypes classified in a previous study (Verhaak et al., 2013), with DIF, IMR, MES,
and PRO representing differentiated, immunoreactive, mesenchymal, and proliferative subtypes, respectively.
(B) Overall survival probabilities (y axis) are plotted against the survival times (months, x axis) of predicted subtype 2 or other patients. The survival curve of all 696
patients with 0.95 confidence intervals is also shown for comparison.
(legend continued on next page)
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2. According to Sharma et al. (2010), despite a lack of inhibitors to
KDM5A, trichostatin A (TSA), an inhibitor to the KDM5A binding
partner histone deacetylases (HDACs), can suppress the drug-
dependent expansion of drug-resistant CSCs. We therefore
postulate that TSA and other HDAC inhibitors can be used to
effectively treat the ovarian subtypes 2, 4, and 5, and that
AEW541, an inhibitor to IGF1R can be used in addition to TSA to
treat subtype2 toprevent chemotherapydrug resistance, thereby
improving the prognosis of these subtypes and ovarian cancers in
general. In addition to HDAC inhibitors and IGF1R inhibitors to
treat drug-resistant CSCs, an inhibitor of TGF-b receptors, such
as SB-431542 (Halder et al., 2005) or the antibody OMP-18R5,
which targets theWnt receptorFrizzled (Gurneyetal., 2012), could
also be considered to treat subtype 2 patients, since the TGF-b
and Wnt signaling pathways are both of great importance in the
EMT. Finally, the poor-prognosis subtypes 4 and 5 may also be
treated using inhibitors of the oncogene SRC (dasatinib),
apoptotic regulator BCR2L1 (navitoclax), or heat shock protein
HSP90B1 (retaspimycin and ganetespib).
On the other hand, we note an interesting observation for sub-
type 7, which shows the longest median survival time. Within
the DNA regions specifically deleted in subtype 7, there are
only three known cancer-related genes: a protein phosphatase
(PPP2R1A), which can negatively regulate cell growth and
division, and two genes related to DNA repair (ERCC1 and
ERCC2; Figure 4). It was previously reported that the expression
level of ERCC1 is negatively correlated with the response to plat-
inum-based chemotherapy (Steffensen et al., 2008; Vella et al.,
2011). This agrees well with our observations (Table S5), as
patients in subtype 4 with upregulated ERCC1 were more likely
to be platinum resistant, whereas patients in subtype 7 were not.
Although we treated each type of feature (DNA methylation,
expression, and CNA) equally in our analysis, DNA methylation
did not appear to be an important signature for subtype classifi-
cation. One reason for this could be the low coverage of DNA
methylation data. The Illumina 27k bead array covers no more
than 0.1% of the total CpGs in the human genome, and the cor-
relation between DNA methylation and gene expression is diffi-
cult to observe when using the methylation state of only a few
CpGs to represent the DNA methylation state of a gene (there
are on average two CpGs per promoter). With deeper whole
genome-wide DNA methylation detection approaches gradually
being adopted, we expect that some of the gene expression
changes (e.g., changes in subtype 2) will be further explained
by epigenetic marks.EXPERIMENTAL PROCEDURES
Data Preprocessing
All data were downloaded from the TCGA (Cancer Genome Atlas Research
Network, 2011). We used all 512 ovarian cancer samples for further analysis(C) Percentage of platinum status, stage, grade, and tumor residue disease of o
(D) Boxplot of the age at initial diagnosis of ovarian cancer patients in predicted s
ranges.
(E) Progression-free survival probabilities (y axis) are plotted against the survival
(F) Overall survival probabilities (y axis) are plotted against the survival time (mo
separately.
See also Figure S4.in which the patients’ survival times or censor times were known and we
had at least the expression and copy number data for the coding genes. The
copy number segmentation data were mapped to the chromosomal positions
of genes and miRNAs to quantitatively measure CNAs.
We used the clinically verified normal ovarian tissue data as controls,
including the gene expression, DNA methylation, and miRNA expression
data for eight samples, and the copy number data for 127 samples.
The TCGA also has intragenic somatic mutation data, but we did not use
them for analysis because they cover only 63.3% (324) of the 512 samples
and cannot be easily quantified.
SelectionofHazardFactorsUsing theCoxProportionalHazardModel
Weused the ‘‘coxph’’ program in the R statistics software to fit a univariate Cox
proportional hazard model (Andersen and Gill, 1982) between each feature
and the survival time of the patients. Samples with missing value(s) were
excluded from the analysis. We then used the Wald test, likelihood ratio test,
and chi-square statistics score test to filter the features. Only the features
that passed the cutoff of p < 0.05 in all three tests were considered to be
related to survival time andwere selected as hazard factors for further analysis.
Adaptive Clustering for De Novo Subtype Identification
We started our clustering analysis with 4,526 features (hazard factors) selected
by Cox regression. One of the 513 samples was not used for the clustering
because it lacked copy number data, which account for 50.4% of all hazard
factors. For each feature of the other 512 samples, missing values were filled
by the median of nonmissing values and then the values were normalized as
follows: Value0 = (Value – Mediancontrols) / STDpatients, where Value0 is a vector
of normalized values, Value is a vector of raw values, Mediancontrols is the
median of normal tissue controls, and STDpatients is the SD of all 512 patients.
In the adaptive clustering step, we used the BIC to determine the optimal
number of clusters among the 512 samples or the 4,526 features (Schwarz,
1978). Because the BIC is mainly aimed at selecting the right number of clus-
ters that will best balance the complexity of the clusteringmodel and its fitness
to data, it does not generate the most compact clustering result in the sense of
least-squared deviations of the data samples to their corresponding cluster
centers. As a result, after the adaptive clustering step, we further employed
the super k-means algorithm to generate the desired compact clustering result
for subsequent analysis (Arthur and Vassilvitskii, 2007; Hartigan and Wong,
1979) (see ‘‘The Adaptive Clustering Algorithm’’ in Extended Experimental
Procedures for more details). When running the super k-means algorithm,
we chose Euclidian distance to calculate the distances between the data
and the cluster centers, and ran the algorithm 1,000 times to obtain the best
clustering result with the lowest sum of squared distances from each point
to its nearest cluster center.
The feature clusters and sample subtypes were further clustered using the
hierarchical clustering algorithm based on the PCC between the centers of
the super k-means clusters.
10-Fold Cross Validation
We performed 10-fold cross validation by randomly dividing the 512 samples
into ten groups and hiding 10% of the samples each time to perform the super
k-means clustering algorithm. The seven subtypes clustered by 90% of the
samples were compared with the original all-sample clustering result, which
was used as a benchmark to calculate the precision and sensitivity. The sensi-
tivity and precision were defined as Sensitivity = true positive=ðtrue positive+
false negativeÞ and Precision= true positive=ðtrue positive+ false positiveÞ.
We then performed 10,000 permutations by randomly assigning the samples
to seven subtypes in order to calculate the empirical p values of the sensitivityvarian cancer patients in predicted subtype 2 and other subtypes.
ubtype 2 and other subtypes. The ends of whiskers represent 1.5 interquartile
times (months, x axis) of predicted subtype 2 or other patients.
nths, x axis) of predicted subtype 2 or other patients within each tumor stage
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and precision. Then the 10% remaining samples or features were assigned to
the nearest cluster centers (Euclidian distance) of the other 90% of samples as
an independent test.
Testing Batch Effects
To examine whether batch effects affected the selection of hazard factors and
the clustering result, we performed Fisher’s exact test with Benjamini-Hoch-
berg correction for each subtype versus each batch.
GO, KEGG, EMT, and hESC-Related Gene Sets Annotation
Enrichment
Annotation enrichments were calculated as described previously (Xia et al.,
2006). Briefly, the enrichment of GO terms (http://www.geneontology.org/),
KEGGpathways (http://www.genome.jp/kegg/), EMT signaling pathways (Pol-
yak and Weinberg, 2009), and hESC-associated gene sets (Ben-Porath et al.,
2008) were calculated by Fisher’s exact test on the systematically detected
signature features of each subtype. A Benjamini-Hochberg-corrected false
discovery rate (FDR)% 0.05 was used to determine the enriched functions.
Literature Cocitations
Literature cocitations were calculated as described previously (Liu et al., 2013).
Building the Cancer Knowledge Base
The knowledge base of cancer-related genes was manually summarized
based on Hanahan andWeinberg’s reviews on the hallmarks of cancer (Hana-
han andWeinberg, 2000, 2011). It contains the genes in the following 25 KEGG
pathways and GO terms: (1) pathways in cancer, (2) MAPK signaling pathway,
(3) mTOR signaling pathway, (4) ErbB signaling pathway, (5) Jak-STAT
signaling pathway, (6) cytokine-cytokine receptor interaction, (7) cell cycle,
(8) PPAR signaling pathway, (9) TGF-b signaling pathway, (10) apoptosis,
(11) telomere maintenance, (12) VEGF signaling pathway, (13) Wnt signaling
pathway, (14) ECM-receptor interaction, (15) adherens junction, (16) focal
adhesion, (17) p53 signaling pathway, (18) base excision repair, (19) mismatch
repair, (20) nucleotide excision repair, (21) inflammatory response, (22) glycol-
ysis/gluconeogenesis, (23) T cell receptor signaling pathway, (24) B cell recep-
tor signaling pathway, and (25) natural killer cell mediated cytotoxicity. It also
contains the genes in ESC pluripotency signaling pathways (http://www.
cellsignal.com/reference/pathway/ESC_pluripotency.html), multi-drug-resis-
tance factors (http://www.biocarta.com/pathfiles/h_mrppathway.asp), and
EMT signaling pathways (Polyak and Weinberg, 2009).
Constructing the Network
We used the human functional protein interaction network constructed by Wu
et al. (2010) as a template to construct the subnetwork among the ovarian can-
cer subtype-specific hallmark genes. Wu et al.’s network template consists of
manually curated interactions (MSKCC Cancer Cell Map [http://cancer.
cellmap.org]; NCI-Nature Pathway Interaction Database [http://pid.nci.nih.
gov]; KEGG [Kanehisa et al., 2004]; BioCarta [http://www.biocarta.com/
genes/index.asp]; Reactome [Vastrik et al., 2007]; TRED [Jiang et al., 2007];
and pantherdb [Mi et al., 2007]) and predicted interactions derived from nonc-
urated sources.
Additional methodologies we developed in this study are described in the
Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Results, Extended Experimental
Procedures, four figures, and four tables and can be found with this article
online at http://dx.doi.org/10.1016/j.celrep.2013.07.010.
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